Literature DB >> 32514592

Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.

Robin Jeannet1,2, Thomas Daix2,3, Rémy Formento1,4, Jean Feuillard1,4, Bruno François5,6,7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32514592      PMCID: PMC7276497          DOI: 10.1007/s00134-020-06127-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, SARS-CoV-2 infection is associated with marked lymphopenia that correlates with morbidity and mortality [1, 2]. Here, we present the first report on serial immunophenotypic and functional changes in 13 consecutively recruited patients infected with SARS-CoV-2 virus during their first week of ICU stay (Supplementary Table 1) with 10 healthy donors used as controls. Patients uniformly exhibited deep global and persisting T, NK and B cell lymphopenia from ICU admission (D0) to day 7 (D7) (Fig. 1a to d). On D0, median absolute lymphocyte count was dramatically reduced at 0.72 [0.65–0.88] G/L as were CD4 and CD8 T cell counts at 0.29 [0.19–0.43] and 0.08 [0.05–0.1] G/L (Fig. 1a, e, f), such CD4 T cell levels reflecting profound immunosuppression in HIV-infected patients. Few CD4 T cells transiently expressed CTLA-4 during the first 3 days (Fig. 1g) while expression of PD-1 was observed at D0 and increased until D7 (Fig. 1h). CD8 T cells significantly and persistently expressed PD-1 from D0 to D7 while CTLA-4 expression remained unchanged (Fig. 1i, j).
Fig. 1

Over time, ICU COVID-19 patients showed a profound and sustained lymphopenia correlated with increased percentages of CD4 and CD8 expressing exhaustion marks and increased frequency of immune suppressive cells. Box plot represent results for 10 healthy subjects (controls) and for the following time point and number of COVID-19 ICU patients. The number of patients is given below the horizontal axis of panel a. Boxes give the median with the first and the third quartile. Whiskers represent min to max. Lines with bracket and plain lines indicate a Mann–Whitney and ANOVA (Kruskall–Wallis test) comparison with controls or during the ICU stay respectively. Test p values are represented by *, ** and *** for p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001 respectively. Upper panel a, b, c, d, e, f: absolute lymphocytes count (ALC) (a), CD3 T-lymphocytes (b), Natural Killer (NK) cells (c), B lymphocytes (d), CD4 (e) and CD8 T cells (f). Light blue boxes represent controls and darker blue boxes represent patients. Middle panel g, h, i, j: percentages of CD4 (g and h) and CD8 (i and j) T cells expressing CTLA-4 (g and i) and PD-1 (h and j). Light green boxes represent controls and darker green boxes represent patients. Lower panel k, l, m, n, o: percentages of CD4 +/CD25 +/CD127low regulatory T cells (T-reg) [3] (k) expressing CTLA-4 (l) and PD-1 (m) and CD14 monocyte counts (n) with quantification of the mHLA-DR at their surface membrane (o). Light orange boxes represent controls and darker orange boxes represent patients

Over time, ICU COVID-19 patients showed a profound and sustained lymphopenia correlated with increased percentages of CD4 and CD8 expressing exhaustion marks and increased frequency of immune suppressive cells. Box plot represent results for 10 healthy subjects (controls) and for the following time point and number of COVID-19 ICU patients. The number of patients is given below the horizontal axis of panel a. Boxes give the median with the first and the third quartile. Whiskers represent min to max. Lines with bracket and plain lines indicate a Mann–Whitney and ANOVA (Kruskall–Wallis test) comparison with controls or during the ICU stay respectively. Test p values are represented by *, ** and *** for p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001 respectively. Upper panel a, b, c, d, e, f: absolute lymphocytes count (ALC) (a), CD3 T-lymphocytes (b), Natural Killer (NK) cells (c), B lymphocytes (d), CD4 (e) and CD8 T cells (f). Light blue boxes represent controls and darker blue boxes represent patients. Middle panel g, h, i, j: percentages of CD4 (g and h) and CD8 (i and j) T cells expressing CTLA-4 (g and i) and PD-1 (h and j). Light green boxes represent controls and darker green boxes represent patients. Lower panel k, l, m, n, o: percentages of CD4 +/CD25 +/CD127low regulatory T cells (T-reg) [3] (k) expressing CTLA-4 (l) and PD-1 (m) and CD14 monocyte counts (n) with quantification of the mHLA-DR at their surface membrane (o). Light orange boxes represent controls and darker orange boxes represent patients Being heterogeneous at D0 (Fig. 1k), percentages of regulatory T cells (Tregs) increased during time. Few of them over-expressed CTLA-4 while PD-1 expression was strongly and stably increased until D7 (Fig. 1l, m). Total granulocytes were moderately increased with a transient egression of immature granulocytes in 4/10 patients at day 4–5 (Supplementary Figure 1). Monocyte counts increased during the first week. Nevertheless, HLA-DR expression was strongly down-regulated by a threefold factor at D0. Strikingly this decrease persisted unabated until D7, possibly impairing antigen presentation, and was associated with increased PD-L1 expression (Fig. 1n, o and Supplementary Figure 4d). Being either an exhaustion or an activation marker, PD-1 is an inducer of CD8 T cell apoptosis when activated. Therefore, functional evaluation of T-lymphocytes was performed in three patients and controls for comparison. Meanwhile production of TNF-α and IL-2 was normal, CD4 T cell IFN-γ production was decreased (Supplementary Figure 2), indicating a CD4 exhaustion process. In contrast, CD8 T cells could be involved in anti-viral immune response since they produced higher levels of IFN-γ and TNF-α (Supplementary Figure 3). Consistently, percentages of effector CD4 T cells were decreased while those of effector memory and activated CD8 T cells were increased (Supplementary Figure 4a to 4c). Circulating levels of IL-6 and IL-8 were moderately but significantly and sustainly increased over time, reflecting the known SARS-CoV-2 related sub-acute inflammatory response of innate immune cells [4] (Supplementary Figure 5). Although our results warrant further confirmation in larger cohort, they strongly suggest a multifaceted devastating effect of the virus to cause depletion of virtually all classes of adaptive immune cells and to cause upregulation of potent T cell killing and immunosuppressive mechanisms in critically-ill COVID-19 patients. Since T cells are essential for definitive viral clearance, these results call into question therapies (e.g., anti-IL-6, corticosteroids, JAK inhibitors) that aim to block the ability of the patient to mount an effective immune response to the invading SARS-CoV-2. Knowing that almost all anti-inflammatory therapies have also chronically failed in sepsis, consideration to therapies that boost host immunity in selected severe ARDS ICU patients (e.g., IL-7, IFN-γ or checkpoint inhibitors) may be appropriate [5, 6]. Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 229 kb) Supplementary material 2 (PDF 551 kb)
  6 in total

1.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.

Authors:  Bruno Francois; Robin Jeannet; Thomas Daix; Andrew H Walton; Matthew S Shotwell; Jacqueline Unsinger; Guillaume Monneret; Thomas Rimmelé; Teresa Blood; Michel Morre; Anne Gregoire; Gail A Mayo; Jane Blood; Scott K Durum; Edward R Sherwood; Richard S Hotchkiss
Journal:  JCI Insight       Date:  2018-03-08

2.  CD4+CD25+CD127- assessment as a surrogate phenotype for FOXP3+ regulatory T cells in HIV-1 infected viremic and aviremic subjects.

Authors:  Julien Saison; Julie Demaret; Fabienne Venet; Christian Chidiac; Christophe Malcus; Francoise Poitevin-Later; Jean-Claude Tardy; Tristan Ferry; Guillaume Monneret
Journal:  Cytometry B Clin Cytom       Date:  2012-09-27       Impact factor: 3.058

Review 3.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

4.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

5.  The many faces of the anti-COVID immune response.

Authors:  Santosha A Vardhana; Jedd D Wolchok
Journal:  J Exp Med       Date:  2020-06-01       Impact factor: 14.307

6.  Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China.

Authors:  Yanrong Wang; Yingxia Liu; Lei Liu; Xianfeng Wang; Nijuan Luo; Ling Li
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

  6 in total
  25 in total

Review 1.  Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19.

Authors:  M Barnova; A Bobcakova; V Urdova; R Kosturiak; L Kapustova; D Dobrota; M Jesenak
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

2.  Co-infection of Klebsiella pneumonia, Cytomegalovirus, Aspergillus and Zygomycete in a patient with SARS-CoV-2.

Authors:  Mihan Pourabdollah Toutkaboni; Atousa Hakamifard; Zahra Abtahian; Arefeh Mirahmadian; Mohammad Rahdar; Mojtaba Mokhber Dezfuli; Payam Tabarsi
Journal:  Clin Case Rep       Date:  2022-07-11

3.  Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.

Authors:  Puneet Rawat; Divya Sharma; Ambuj Srivastava; Vani Janakiraman; M Michael Gromiha
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

4.  High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19.

Authors:  Marco De Zuani; Petra Lazničková; Veronika Tomašková; Martina Dvončová; Giancarlo Forte; Gorazd Bernard Stokin; Vladimir Šrámek; Martin Helán; Jan Frič
Journal:  Scand J Immunol       Date:  2021-12-13       Impact factor: 3.889

5.  T-cell dysregulation in COVID-19.

Authors:  Bahire Kalfaoglu; José Almeida-Santos; Chanidapa Adele Tye; Yorifumi Satou; Masahiro Ono
Journal:  Biochem Biophys Res Commun       Date:  2020-11-07       Impact factor: 3.575

6.  Cytomegalovirus haemorrhagic enterocolitis associated with severe infection with COVID-19.

Authors:  Warren C Carll; Mohamed Y Rady; Marcela A Salomao; Bhavesh Patel; Vijay P Singh; Ayan Sen
Journal:  BMJ Open Gastroenterol       Date:  2021-01

Review 7.  Viral coinfections in COVID-19.

Authors:  Parisa S Aghbash; Narges Eslami; Milad Shirvaliloo; Hossein B Baghi
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

8.  Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network.

Authors:  Claire Dupuis; Etienne de Montmollin; Niccolò Buetti; Dany Goldgran-Toledano; Jean Reignier; Carole Schwebel; Julien Domitile; Mathilde Neuville; Moreno Ursino; Shidasp Siami; Stéphane Ruckly; Corinne Alberti; Bruno Mourvillier; Sebastien Bailly; Virginie Laurent; Marc Gainnier; Bertrand Souweine; Jean-François Timsit
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

Review 9.  Haemophagocytic syndrome and COVID-19.

Authors:  Soledad Retamozo; Pilar Brito-Zerón; Antoni Sisó-Almirall; Alejandra Flores-Chávez; María-José Soto-Cárdenas; Manuel Ramos-Casals
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

10.  Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.

Authors:  Anahita Rouzé; Ignacio Martin-Loeches; Pedro Povoa; Demosthenes Makris; Antonio Artigas; Mathilde Bouchereau; Fabien Lambiotte; Matthieu Metzelard; Pierre Cuchet; Claire Boulle Geronimi; Marie Labruyere; Fabienne Tamion; Martine Nyunga; Charles-Edouard Luyt; Julien Labreuche; Olivier Pouly; Justine Bardin; Anastasia Saade; Pierre Asfar; Jean-Luc Baudel; Alexandra Beurton; Denis Garot; Iliana Ioannidou; Louis Kreitmann; Jean-François Llitjos; Eleni Magira; Bruno Mégarbane; David Meguerditchian; Edgar Moglia; Armand Mekontso-Dessap; Jean Reignier; Matthieu Turpin; Alexandre Pierre; Gaetan Plantefeve; Christophe Vinsonneau; Pierre-Edouard Floch; Nicolas Weiss; Adrian Ceccato; Antoni Torres; Alain Duhamel; Saad Nseir
Journal:  Intensive Care Med       Date:  2021-01-03       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.